Management of Paediatric Patients With Medically Refractory Crohn’s Disease Using Ustekinumab: A Multi-Centred Cohort Study

Ustekinumab [UST] is effective in the treatment of adults with moderate to severe Crohn’s disease [CD]. There is a paucity of data on its use in children. To evaluate the response to UST in children with moderate to severe CD. This multicentre retrospective cohort study identified children under 18 years old with CD, who received open-labelled subcutaneous UST. The primary outcome was changes in mean abbreviated Paediatric Crohn’s Disease...